{"changes":[],"country":"US","description":"Electra Therapeutics develops first-in-class monoclonal antibodies targeting signal regulatory proteins (SIRPs) on immune cells, led by ELA026 for secondary hemophagocytic lymphohistiocytosis. It treats sHLH (100% Phase 1b 8-week survival) and is expanding into hematologic cancers. Electra's SIRP antibodies spare the CD47/SIRPα checkpoint.","domain":"electratherapeutics.com","employees":null,"founded":2018,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":37.65354,"lng":-122.416866,"location":"South San Francisco CA","name":"Electra Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":183000000,"currency":"USD","date":"2025-10-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-02","status":"attributed","url":null},"status":"attributed","type":"series-c","url":null}],"slug":"electratherapeutics-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-02","status":"attributed","url":null},{"fact":"existence","publisher":"electratherapeutics.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://electratherapeutics.com"},{"fact":"description","publisher":"electratherapeutics.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://electratherapeutics.com"}],"stage":"series-b+","techStack":[],"totalRaisedUsd":300000000,"updatedAt":"2026-05-02"}